A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

IsraelRecruitingPHASE2

Conditions

Ovarian Neoplasms · Breast Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • GSK Clinical Trials

    Study Director

    GlaxoSmithKline